Previously, there is no study looking at serum biomarkers for epilepsy. Epilepsy can trigger neuroinflammation events, and serum amyloid A (SAA) is one biomarker as acute-phase protein in multiple diseases. In present study, we detected serum SAA peak in epileptic patients with mass spectrometry and quantified with enzyme-linked immunosorbent assay measurement. The results suggested that in acute phase of epilepsy, the serum SAA increased, but after 3 months of treatment, the SAA peak was disappeared. In conclusion, the study provided values of proteomic diagnosis of epilepsy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/00207454.2012.756876 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!